Artificial intelligence (AI) has been used to refine the specificity of genome editing, potentially reducing off-target effects and improving editing safety and efficiency. The work, by researchers at Mass General Brigham, Boston, Massachusetts, is published in Nature.

By using a novel machine-learning algorithm named PAMmla, the team were able to 'dramatically [expand the] repertoire of effective and safe CRISPR/Cas9 enzymes,' said corresponding author Dr Benjamin Kleinstiver of Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

For more details of this story, please visit News-Medical.